|1.||Campàs, Clara: 5 articles (08/2015 - 05/2003)|
|2.||Colomer, Dolors: 3 articles (08/2015 - 05/2003)|
|3.||de Frias, Mercè: 3 articles (02/2014 - 10/2010)|
|4.||Swinnen, Johannes V: 3 articles (12/2011 - 03/2005)|
|5.||Camici, M: 3 articles (01/2006 - 06/2000)|
|6.||Garcia-Gil, M: 3 articles (01/2006 - 06/2000)|
|7.||Tozzi, M G: 3 articles (01/2006 - 06/2000)|
|8.||Pesi, R: 3 articles (01/2006 - 06/2000)|
|9.||Roué, Gaël: 2 articles (08/2015 - 02/2014)|
|10.||Montraveta, Arnau: 2 articles (08/2015 - 02/2014)|
08/01/1992 - "Acadesine can afford sustained functional protection against injury during extended periods of ischemia and reperfusion. "
03/01/2001 - "Acadesine significantly reduced the number of injured alveoli when given before ischemia (4% +/- 1%) or reperfusion (6% +/- 2%) but not when administered after reperfusion (62% +/- 8%). "
03/01/2001 - "Animals were subjected to one of the following three protocols: acadesine administered IV 15 min before ischemia (Group 3), 15 min before reperfusion (Group 4), or 30 min after reperfusion (Group 5). "
11/01/1995 - "Thereafter, acadesine (0.5 mg.kg-1.min- i.v.) was given continuously during ischemia and 30 min after reperfusion. "
11/01/1995 - "Six cats received saline, and six cats were treated initially before ischemia with acadesine (2.5 mg/kg body wt i.v.) over 5 min as a bolus. "
01/01/2008 - "Protherics presented 2-year mortality results from a study of acadesine, investigating long-term mortality after perioperative myocardial infarction, at the 55th Scientific Session of the American College of Cardiology in 2006.Previously, Gensia Sicor conducted clinical trials of acadesine in Canada, the EU and the US; results of these trials were inconclusive. "
10/01/1995 - "Acadesine did not significantly affect the incidence of myocardial infarction in the overall study population, but it significantly reduced the incidence of Q-wave myocardial infarction in high-risk patients (placebo, 19.7%; acadesine, 10.0%; p = 0.032). "
01/01/1993 - "Acadesine lowers temporal threshold for the myocardial infarct size limiting effect of preconditioning."
01/01/1992 - "Failure of AICA riboside to limit infarct size during acute myocardial infarction in rabbits."
08/01/2008 - "Further studies are required to determine the efficacy of acadesine for other ischaemic indications, including during percutaneous transluminal coronary angioplasty for acute myocardial infarction."
06/01/1991 - "Additionally, two doses of 500 mg/kg of 5-aminoimidazole-4-carboxamide riboside yielded a mean percentage of rat skin flap necrosis (12.24% +/- 4.58%) much lower (21.68% +/- 3.18%) than that of the control group of rats (p = 0.056). "
06/01/1991 - "When 300 or 500 mg/kg of 5-aminoimidazole-4-carboxamide riboside was given as a single dose, the mean percentage of rat skin flap necrosis (19.4% +/- 3.1% and 19.6% +/- 4.2%, respectively) was lower but not significantly different from that of the control group of rats (29.3% +/- 2.7%) (p less than 0.08). "
06/01/1991 - "Our blinded fashion study demonstrated an almost statistically significant reduction of random skin flap distal necrosis after intraperitoneal injection of high doses of 5-aminoimidazole-4-carboxamide riboside.(ABSTRACT TRUNCATED AT 250 WORDS)"
06/01/1991 - "5-Aminoimidazole-4-carboxamide riboside, a naturally occurring by-product in purine biosynthesis, stimulates the release of ischemic cell adenosine and indirectly blocks the granulocyte-induced tissue necrosis. "
01/01/1992 - "This study examined whether the adenosine potentiator, 5-aminoimidazole-4-carboxamide riboside (AICAr), could limit tissue necrosis during acute myocardial infarction in rabbit hearts with minimal coronary collateral flow. "
02/01/2013 - "A HPLC method for simultaneous determination of 5-aminoimidazole-4-carboxamide riboside and its active metabolite 5-aminoimidazole-4-carboxamide ribotide in tumor-bearing nude mice plasma and its application to pharmacokinetics study."
02/15/2014 - "Gene expression profiling analysis in harvested tumors suggested that acadesine modulates immune response, actin cytoskeleton organization and metal binding, pointing out a substantial impact on metabolic processes by the nucleoside analog. "
07/01/2013 - "A more pronounced cytotoxicity for tumor cells, as well as the non-canonical death mechanism(s), makes acadesine a promising candidate for antitumor therapy. "
07/01/2013 - "In tumor cells, acadesine triggered non-apoptotic death; the potency of the compound to normal cells was substantially lower. "
07/01/2013 - "We studied the cytotoxicity of acadesine (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) for tumor and normal cells of various species and tissue origin. "
07/04/2006 - "Acadesine is the first therapy proven to be effective for reducing the severity of acute post-reperfusion MI, substantially reducing the risk of dying over the 2 years after infarction."
10/01/1995 - "In patients with Q-wave infarction, the high-dose acadesine group had a lower peak median CK-MB (P = 0.042) and area under the CK-MB curve (P = 0.021). "
05/01/1995 - "However, when reperfusion was extended to 6 h (group 6) acadesine could no longer restore protection [36.2(0.9)% infarction]. "
05/01/1995 - "Additionally, treatment with acadesine alone did not modify infarct size (group 7) [39.5(4.0)%], but acadesine largely restored the protection of ischaemic preconditioning despite a 4 h reperfusion interval (group 5) [20.4(3.0)% infarction, P < 0.01 v control]. "
03/01/1994 - "Treatment with acadesine alone did not modify the infarct size [37.8(3.5)%], but both of the acadesine plus preconditioning groups showed a significant limitation of infarct size with 13.9(3.1)% infarction in group 4 and 12.7(2.2)% infarction in group 5 (both p < 0.01 v control). "
|1.||AICA ribonucleotide (CAIR)
|5.||St. Thomas' Hospital cardioplegic solution
|7.||Adenosine Triphosphate (ATP)
|1.||Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)
|4.||Induced Heart Arrest (Cardioplegia)
|5.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)